Equity Details
Price & Market Data
Price: $14.53
Daily Change: -$0.93 / 6.40%
Daily Range: $13.60 - $15.38
Market Cap: $421,651,072
Daily Volume: 341,907
Performance Metrics
1 Week: 0.35%
1 Month: 1.82%
3 Months: 2.83%
6 Months: 32.21%
1 Year: 161.8%
YTD: -7.86%
About Enanta Pharmaceuticals, Inc. (ENTA)
Daily market data for Enanta Pharmaceuticals, Inc. (ENTA). Current price: 14.53, daily change: -$0.93 / 6.40%. Market cap: 421,651,072. Performance 1-week and 52-week.
Company Details
Employees: 120
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.